Full-Time

Business Manager

Multiple Teams

Posted on 7/6/2026

Deadline 7/14/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Phoenix, AZ, USA

In Person

Field-based role; willing to travel up to 80% in the United States.

Category
Sales & Account Management (1)
Required Skills
Sales

People at Johnson & Johnson

People at Johnson & Johnson who can refer or advise you

Requirements
  • Minimum of a BA/BS, combined with a minimum of 7 years professional work experience.
  • 5+ years of sales experience in cardiovascular, vascular, and/or interventional cardiology medical devices or closely related market. Notably, selling, supporting, and managing cardiac imaging structural heart products and therapies (including ICE, TAVI, LAAO, M/T TEER, TTVR, PFO, ASD and Cardiac Imaging) is preferred.
  • Breadth and depth relationships within interventional cardiologists.
  • Strong analytical, project management, and communication skills.
  • Experience working in a matrixed organization and collaborating across functions. Knowledge of healthcare regulations and compliance requirements.
Responsibilities
  • Partners with doctors and Cath lab administrators to set up equipment evaluations and facilitate solutions to issues in a timely manner.
  • Develop and execute selling strategies and strategic sales plans to achieve and exceed sales objectives.
  • Own territory strategy includes account prioritization, procedural targeting, and ICE adoption roadmaps across structural heart programs – inclusive of market development efforts.
  • Create tactical and operational plans, clearly communicating these to UCASs, RBDs, and other JNJMT CV team members.
  • Leads and coordinates UCAS pod activity by coordinating strategic efforts in order to drive product utilization throughout the assigned territory. Maintains regular communication with teammates to ensure alignment and consistency in providing optimal customer service, while maximizing time and effort.
  • Demonstrate deep product and procedural knowledge, clinical and procedural excellence, and expertise in new product introductions.
  • Serves as a source of information and support to pod members and internal partners in identifying trends, understanding competitive conditions, and sharing knowledge of best practices within the marketplace.
  • Capture and communicate voice of customer insights to clinical science, medical affairs, marketing, and R&D teams to inform product development, clinical evidence generation and commercial strategy.
  • Leverages J&J business partners (cross functionally and across business units) within customer accounts and overlapping geographies to maximize the use of resources and increase business outcomes.
  • Responsible for communicating business related issues or opportunities to next management.
  • Partners with the TMs, UCASs and RBDs to identify and resolve case issues and provide support to engender customer group loyalty and increase business outcomes.
  • Adheres to all Company guidelines related to Health, Safety and Environmental practices. Ensure that all resources needed to meet Company guidelines are available and in good condition.
  • Proactively ensures personal, pod and Company compliance with all Federal, State, local and Company regulations, policies, and procedures.
  • Provides mentoring for new sales staff members as assigned.
  • Organizes and completes administrative responsibilities efficiently, including timely completion of compliance training, submission of expense reports, samples reporting and other requests and assignments. Meets Company quality standards and established deadlines.
  • Maintain company vehicle safety protocols (Safe Fleet) in accordance with all company guidelines.
  • Stays current in emerging technology and techniques and all aspects of company new product launches and competitive entries.
  • Facilitates customer adoption of new products, technologies, and techniques.
  • Responsible for communicating business-related issues or opportunities to next management level.
  • Responsible for ensuring subordinates follow all Company guidelines related to Health, Safety and Environmental practices and that all resources needed to do so are available and in good condition.
  • Responsible for ensuring personal and Company compliance with all Federal, State, local and Company regulations, policies, and procedures.
  • Stay current on industry best practices and emerging technologies in interventional cardiology and structural heart.
  • Actively collaborate with EP commercial team(s) on adoption plans from targeting (constructive collaboration identification) to implementation, to ensuring we cross support one another as needed.
Desired Qualifications
  • Business Development
  • Business Savvy
  • Customer Centricity
  • Healthcare Trends
  • Interpersonal Influence
  • Market Knowledge
  • Objectives and Key Results (OKRs)
  • Presentation Design
  • Process Improvements
  • Revenue Management
  • Sales
  • Solutions Selling
  • Stakeholder Engagement
  • Strategic Sales Planning
  • Sustainable Procurement
  • Technical Credibility
  • Vendor Selection

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

People at Johnson & Johnson

People at Johnson & Johnson who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • MedTech division targets mid-single-digit growth via cardiovascular acquisitions like Shockwave and Abiomed.
  • Oncology portfolio strengthened by MonumenTAL-3 data for TALVEY in relapsed/refractory multiple myeloma.
  • FDA approval of dual-energy cardiac ablation platform enables phased US commercial rollout starting summer 2026.

What critics are saying

  • Talc litigation includes a $1.5 billion verdict and 68,000+ pending cases with no global settlement by 2026.
  • Bankruptcy shield dismissed in 2025, exposing J&J to direct liability and massive payouts within 6–12 months.
  • China sales face headwinds from volume-based procurement, with pressures persisting through second half of 2026.

What makes Johnson & Johnson unique

  • J&J operates across medicine, medical devices, and consumer health, unlike pure biopharma peers.
  • It leads in bispecific oncology with TALVEY and advances next-generation tri-specific antibodies.
  • J&J separates orthopaedics to focus on high-growth medicine and MedTech segments over 24 months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-1%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.